PETMED EXPRESS INC

(a) Employment Agreement Amendment and RSA Award with Interim Chief Executive Officer and President

As reported on a Current Report on Form 8-K filed by the Company on October 21, 2025, on October 20, 2025, the Company entered into an Interim Executive Employment Agreement with Leslie C.G. Campbell that governs the terms of Ms. Campbell’s role as Interim Chief Executive Officer and President of the Company (the “Employment Agreement”). The Employment Agreement provides that Ms. Campbell will serve as Interim Chief Executive Officer and President of the Company for a term of one year beginning on August 11, 2025. On August 10, 2026, the Company and Ms. Campbell entered into an Amendment No. 1 to Interim Executive Employment Agreement (“Amendment No. 1”) under which the Employment Agreement was amended to provide that Ms. Campbell’s term of employment thereunder would continue without a specified expiration date until Ms. Campbell’s employment is terminated by either the Company or Ms. Campbell. The Employment Agreement, as amended by Amendment No. 1, provides that Ms. Campbell’s employment may be terminated at any time and for any reason, with or without cause, by delivering written notice of termination to the other party. No other provisions of the Employment Agreement were modified by Amendment No. 1.

On August 11, 2026, the Board of Directors of the Company (the “Board”), upon the recommendation of the Board’s Compensation and Human Capital Committee, approved and granted an award of 60,000 restricted shares of common stock (the “RSA Award”) to Ms. Campbell under the Company’s 2024 Omnibus Incentive Plan (the “Plan”) as an incentive for Ms. Campbell to assist with the transition of her responsibilities to a new CEO when and as the Board selects the new CEO. The RSA Award will vest on the first anniversary of the grant date of the award so long as Ms. Campbell continues to be a full-time employee of the Company as of such date, provided that the RSA Award will vest earlier on an accelerated basis on (i) the date of Ms. Campbell’s death or Disability (as defined the Plan) or upon a Change of Control (as defined in the Plan), or (ii) the date that is 60 days after the date on which Ms. Campbell ceases to be the Company’s Interim CEO and President as a result of the Company appointing a new CEO and President, provided Ms. Campbell continues to work for the Company on a full time basis during such 60-day period (the “Transition Period”) at her then-current base salary in a non-CEO capacity to provide reasonable assistance as requested by the Board or the new CEO with the transition of duties to the new CEO (provided that the Board shall have the discretion to reduce the duration of the Transition Period upon written notice to Ms. Campbell). The RSA Award otherwise contains the same terms, conditions, and provisions as the Company’s standard form of restricted stock award grant under the Plan.

The above description of Amendment No. 1 does not purport to be a complete description of Amendment No. 1 and is qualified in its entirety by reference to the full text of Amendment No. 1, which is attached as Exhibit 10.4 and incorporated herein by this reference.

(b) Not applicable.

(c) During the three months ended June 30, 2026, no director or officer (as defined in Rule 16a-1(f) of the Exchange Act) of the Company adopted, modified, orterminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K.